Finerenone, a selective mineralocorticoid receptor antagonist, has been proven to reduce albuminuria in patients with chronic kidney disease (CKD) and type 2 diabetes in previous trials. Recently, a clinical trial reported the long-term effects of f...

The impact of blood glucose control on the degree of required medical interventions and mortality in patients with COVID-19 and T2DM remains uncertain. A recent retrospective study involving 7337 patients with COVID-19, among which 952 cases had pre...